Please login to the form below

Not currently logged in
Email:
Password:

RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

The EMA has laid out monitoring and mitigation strategies for these side effects, including the use of Roche’s RoActemra to treat CRS.

Latest news

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Achieving remission Achieving remission

    Campaign:RoACTEMRA / ACTEMRA: beyond the boundaries of existing treatments. Timescale:2008 to 2009. ... Online monitoring tools tracked RoACTEMRA / ACTEMRA noise, identifed top influencers and tonality of digital conversations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • Infographic: RA Perceptions

    Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market

  • Brand leaders in RA will lose market share, predict rheumatologists

    leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics